AG
Artal Group Portfolio holdings
AUM
$930M
This Quarter Return
+5.69%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$1.68B
AUM Growth
+$1.68B
(-3%)
Cap. Flow
-$39M
Cap. Flow
% of AUM
-2.32%
Top 10 Holdings %
Top 10 Hldgs %
48.34%
Holding
151
New
26
Increased
23
Reduced
14
Closed
33
Top Buys
| 1 |
Revolution Medicines
RVMD
|
$23.2M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$20.9M |
| 3 |
Ventyx Biosciences
VTYX
|
$18M |
| 4 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$13.1M |
| 5 |
Cytokinetics
CYTK
|
$12.9M |
Top Sells
Sector Composition
| 1 | Healthcare | 94.05% |
| 2 | Consumer Discretionary | 5.18% |
| 3 | Real Estate | 0.31% |
| 4 | Financials | 0.29% |
| 5 | Technology | 0.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Lexicon Pharmaceuticals
LXRX
$400M
| $218M | 12.96% | 89,778,234 | – | – |
|
|
ONC
2
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $108M | 6.42% | 501,335 -98,665 | -16% | -$21.3M |
|
|
3
Apellis Pharmaceuticals
APLS
$3.48B
| $80.2M | 4.77% | 1,216,312 +316,312 | +35% | +$20.9M |
|
4
Scholar Rock
SRRK
$3.14B
| $72.2M | 4.29% | 9,027,950 +47,680 | +0.5% | +$381K |
|
|
MORF
5
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $68.3M | 4.06% | 1,813,949 -336,051 | -16% | -$12.6M |
|
|
WW
6
DELISTED
WW International
WW
| $61.1M | 3.63% | 14,818,300 | – | – |
|
|
MRTX
7
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $57.2M | 3.4% | 1,537,709 -295,049 | -16% | -$11M |
|
8
Kymera Therapeutics
KYMR
$2.95B
| $53.5M | 3.18% | 1,805,346 -194,654 | -10% | -$5.77M |
|
|
9
Cytokinetics
CYTK
$4.23B
| $48.1M | 2.86% | 1,367,023 +367,023 | +37% | +$12.9M |
|
|
SWTX
10
DELISTED
SpringWorks Therapeutics
SWTX
| $46.8M | 2.78% | 1,817,349 -182,651 | -9% | -$4.7M |
|
|
CERE
11
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $46.7M | 2.77% | 1,914,466 +14,466 | +0.8% | +$353K |
|
|
12
Revolution Medicines
RVMD
$7.1B
| $44.9M | 2.67% | 2,070,988 +1,070,988 | +107% | +$23.2M |
|
13
Amicus Therapeutics
FOLD
$2.34B
| $39.1M | 2.32% | 3,526,407 -473,593 | -12% | -$5.25M |
|
|
IGMS
14
DELISTED
IGM Biosciences
IGMS
| $34.5M | 2.05% | 2,509,972 +59,972 | +2% | +$824K |
|
15
Krystal Biotech
KRYS
$4.27B
| $33M | 1.96% | 412,082 +12,082 | +3% | +$967K |
|
|
SAGE
16
DELISTED
Sage Therapeutics
SAGE
| $31.5M | 1.87% | 750,000 | – | – |
|
17
Relay Therapeutics
RLAY
$619M
| $27.6M | 1.64% | 1,673,743 +219,027 | +15% | +$3.61M |
|
18
Sea Limited
SE
$110B
| $26.2M | 1.56% | 302,500 +130,000 | +75% | +$11.3M |
|
|
AGEN
19
Agenus
AGEN
$133M
| $23.8M | 1.41% | 15,631,235 +1,131,235 | +8% | +$1.72M |
|
|
KLRS
20
Kalaris Therapeutics, Inc. Common Stock
KLRS
$76.3M
| $22M | 1.31% | 5,577,167 | – | – |
|
|
VIGL
21
DELISTED
Vigil Neuroscience
VIGL
| $22M | 1.31% | 2,243,352 | – | – |
|
22
Kura Oncology
KURA
$686M
| $21M | 1.25% | 1,718,056 +18,056 | +1% | +$221K |
|
23
Denali Therapeutics
DNLI
$2.23B
| $18.5M | 1.1% | 802,899 +2,899 | +0.4% | +$66.8K |
|
24
Schrodinger
SDGR
$1.44B
| $18.4M | 1.1% | 700,000 | – | – |
|
25
Seer Inc
SEER
$115M
| $18.3M | 1.09% | 4,750,000 | – | – |
|